Press Release

Addiction Disorders Drugs Market to Grow with a CAGR of 8.95% through 2028

Increasing prevalence, the opioid epidemic, and pharmaceutical innovation are expected to drive the Global Addiction Disorders Drugs Market growth in the forecast period, 2024-2028.


According to TechSci Research report, “Addiction Disorders Drugs Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Addiction Disorders Drugs Market stood at USD 10.19 billion in 2022 and is anticipated to grow with a CAGR of 8.95% in the forecast period, 2024-2028. This can be attributed to the post-pandemic impact. The COVID-19 pandemic brought new challenges to addiction treatment, including increased stress, social isolation, and disruptions in care delivery. As societies adapt to the post-pandemic landscape, addressing the mental health and addiction-related consequences is expected to be a driving force in the market.

Furthermore, psychedelic-assisted therapy is gaining recognition as a potential treatment option for certain addictive disorders, such as alcohol and tobacco addiction. Clinical trials are exploring the therapeutic benefits of substances like psilocybin and MDMA in controlled settings.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Addiction Disorders Drugs Market.”


The industry is experiencing rapid expansion, driven by several key factors, including heightened awareness of available treatments and the increasing prevalence of substance abuse disorders. Furthermore, supportive government initiatives, such as drug awareness campaigns and prevention programs, are anticipated to fuel industry growth over the forecast period. Substance abuse refers to the misuse of illegal drugs, prescription or over-the-counter medications, or alcohol, either in quantities exceeding recommended limits or for purposes other than their intended use. Such misuse can lead to a range of social, physical, emotional, and occupational challenges for individuals.

In 2021, cannabis emerged as the most commonly used substance worldwide, with an estimated 192 million users. Opioids, on the other hand, pose the greatest threat, with the number of deaths attributable to opioid use disorders rising by 71% over the past decade, particularly among women, where there was a 92% increase compared to a 63% increase among men. The escalating rates of addiction within the population underscore the imperative to raise awareness about the health risks posed by illicit drugs. Both public and private organizations are diligently organizing campaigns and initiatives aimed at educating people about the detrimental effects of substance abuse and promoting the adoption of addiction treatment among those struggling with addiction.

For instance, in March 2022, the Texas Health and Human Services launched a USD 23.2 million public awareness campaign focused on preventing substance abuse disorders and facilitating access to addiction treatment and services. Additionally, the growing uptake of Nicotine Replacement Therapy (NRT) due to increased public awareness of the harmful effects associated with smoking presents an opportunity for market expansion. The acceptance of NRT is expected to rise further with advancements in therapy, including the introduction of innovative products such as flavored chewing gums, heat-not-burn products, and lozenges.

For instance, in February 2023, Sesh+, a company dedicated to smoking cessation and addiction treatment, introduced NRT products in flavors like cinnamon, pomegranate, and wintergreen, aimed at boosting treatment adoption. However, industry growth is hindered by the challenge of addiction relapse following the discontinuation of therapies. According to estimates from the National Institute on Drug Abuse, 40-60% of individuals experience relapse within 30 days of leaving an inpatient addiction treatment center, with nearly 85% relapsing within the first year of treatment. Patients are prescribed medications to help alleviate cravings and restore healthy brain function, as these medications also aid in managing withdrawal symptoms during the initial detoxification phase, which marks the first step in addiction treatment.

The Global Addiction Disorders Drugs Market is segmented into type, end-use, regional distribution, and company.

Based on its type, the tobacco/nicotine and vaping sector claimed the largest portion of total revenue in 2022. This sector's prominence can be attributed to the rising prevalence of tobacco addiction within the population. It is estimated that approximately 22.3% of the global population is tobacco users, resulting in the annual loss of 8 million lives. Tobacco is often considered a gateway substance, as it can lead to the use and abuse of other substances. Teenagers who smoke are 22 times more likely to use cocaine, 8 times more likely to use marijuana, and 3 times more likely to consume alcohol compared to non-smokers. Tobacco is associated with causing harm to nearly every organ in the body, including lung impairment and decreased lung function. This underscores the pressing need for addiction treatment for individuals dealing with such health conditions.

On the other hand, the alcohol sector is anticipated to exhibit the most rapid growth rate in the foreseeable future, owing to its widespread consumption, easy availability, and increased social acceptance, leading to higher global consumption. According to estimates from the World Health Organization (WHO), 3 million deaths occur worldwide each year due to the harmful use of alcohol, representing 5.3% of all fatalities. Following tobacco addiction, alcohol abuse is the second most prevalent form of substance abuse on a global scale. Alcohol use disorder arises when a person's drinking habits result in distress or harm, affecting approximately 10% of adult men and 5% of adult women. The market for alcohol addiction treatment is projected to experience significant growth during the forecast period, including the utilization of key drugs such as disulfiram, acamprosate, and naltrexone for alcohol addiction treatment.

Based on end-use, the hospital segment within the industry emerged as the dominant force in 2022, securing the largest portion of the total revenue. This dominance can be attributed to several factors. Firstly, there is a delay in the detection of addiction-related conditions due to social stigmatization among patients. This leads to reluctance on their part to seek treatment, resulting in the development of severe addiction cases that necessitate hospitalization for comprehensive addiction treatment. This, in turn, propels the growth of this segment. Additionally, individuals engaged in prolonged substance abuse often suffer from other health issues, such as cardiovascular disease, stroke, cancer, HIV/AIDS, Hepatitis B and C, lung ailments, and mental disorders. Hospitals, as primary treatment centers, also offer services to address these health conditions linked to substance abuse.

Conversely, the rehabilitation centers segment is expected to exhibit the most rapid CAGR during the forecast period. Rehabilitation centers provide a wider array of treatment options, amenities, and specialized care, including dual diagnosis, making them the preferred choice for patients requiring long-term addiction treatment programs, which may span from six months to a year or longer. Furthermore, rehabilitation centers are forging partnerships with hospitals to enhance patient care. However, it's worth noting that the high cost associated with addiction treatment within rehabilitation centers is anticipated to act as a hindrance to the growth of this segment. For instance, a general outpatient rehab program costs between USD 1,400 to USD 10,000 over 30 days, averaging around USD 5,700 per month. It's important to note that addiction treatment pharmaceutical products represent only a fraction of these overall costs.

 Major companies operating in Global Addiction Disorders Drugs Market are:

  • Teva Pharmaceutical Industries Ltd
  • Abbott Laboratories Inc
  • Cipla Ltd
  • Eli Lilly and Co Ltd
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Dr. Reddy's Laboratories Limited
  • Viatris Inc.
  • AstraZeneca PLC

 Download Free Sample Report

Customers can also request for 10% free customization on this report.


“The Global Addiction Disorders Drugs Market is on the cusp of significant transformation, with the upcoming trends poised to reshape the landscape of addiction treatment. Personalized medicine, telemedicine, expanded medication options, and innovative therapeutic approaches promise to make treatment more effective and accessible. As research and awareness continue to evolve, the market is well-positioned to provide hope and support to individuals and communities grappling with addiction disorders in the years ahead,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Addiction Disorders Drugs Market By Type (Tobacco/Nicotine & Vaping, Alcohol, Marijuana, Synthetic Cannabinoids, Prescription & Over-the-Counter Medications, Others), By End-Use (Hospitals, Clinics, Rehabilitation Centers, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Addiction Disorders Drugs Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Addiction Disorders Drugs Market.



Mr. Ken Mathews

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]


Relevant News